Preventing hepatitis B reactivation due to immunosuppressive drug treatments

JAMA - Journal of the American Medical Association

Volumn 313, Issue 16, 2015, Pages 1617-1618

  Perrillo, Robert P ^a   Martin, Paul ^b   Lok, Anna S ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; NEUTRALIZING ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB; TENOFOVIR; TUMOR NECROSIS FACTOR ANTIBODY; VINCRISTINE SULFATE; VIRUS DNA;

ANTIVIRAL THERAPY; BIOLOGICAL THERAPY; BLOOD EXAMINATION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMOPROPHYLAXIS; DEATH; DISEASE SEVERITY; DRUG CHOICE; DRUG INFORMATION; DRUG USE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER FAILURE; LIVER INJURY; LYMPHOMA; MORTALITY; NOTE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS REACTIVATION; IMMUNOLOGY; PHYSIOLOGY; RISK;

HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; RISK;

EID: 84928734783     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.2571     Document Type: Note

References (10)

1. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1): 221-244.e3.
2. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519-528.
3. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma. J Clin Oncol. 2014;32(33):3736-3743.
4. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306-1311.
5. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20.
6. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy. JAMA. 2014;312(23):2521-2530.
7. Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2014;70(1):178-186.
8. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
9. Stine JG, Khokhar OS, Charalambopoulos J, et al. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res (Hoboken). 2010;62(5):704-711.
10. Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs. Hepatology. 2015;61(2):703-711.